Abstract HIV-associated sensory neuropathy (HIV-SN) is the most frequent manifestation of HIV disease. It often presents with significant neuropathic pain and is associated with previous exposure to neurotoxic nucleoside reverse transcriptase inhibitors. However, HIV-SN prevalence remains high even in resource-rich settings where these drugs are no longer used. Previous evidence suggests that exposure to indinavir, a protease inhibitor commonly used in antiretroviral therapy, may link to elevated HIV-SN risk. Here, we investigated whether indinavir treatment was associated with the development of a "dying back" axonal neuropathy and changes in pain-relevant limb withdrawal and thigmotactic behaviours. After 2 intravenous injections of indinavir (50 mg/kg, 4 days apart), adult rats developed hind paw mechanical hypersensitivity, which peaked around 2 weeks post first injection (44% reduction from baseline). At this time, animals also had (1) significantly changed thigmotactic behaviour (62% reduction in central zone entries) comparing with the controls and (2) a significant reduction (45%) in hind paw intraepidermal nerve fibre density. Treatment with gabapentin, but not amitriptyline, was associated with a complete attenuation of hind paw mechanical hypersensitivity observed with indinavir treatment. Furthermore, we found a small but significant increase in microglia with the effector morphology in the lumbar spinal dorsal horn in indinavir-treated animals, coupled with significantly increased expression of phospho-p38 in microglia. In summary, we have reported neuropathic pain-related sensory and behavioural changes accompanied by a significant loss of hind paw skin sensory innervation in a rat model of indinavir-induced peripheral neuropathy that is suitable for further pathophysiological investigation and preclinical evaluation of novel analgesics.
Introduction
HIV-associated sensory neuropathy (HIV-SN) is the most frequent neurological manifestation of HIV disease and is seen in 40% to 50% of patients whose HIV disease is otherwise well controlled by antiretroviral therapy (ART). 21, 23, 45 HIV-SN is a distal symmetrical, predominantly sensory, polyneuropathy. The symptoms of HIV-SN present with a characteristic gloves and socks distribution and it is associated with significant neuropathic pain. 1, 12, 30, 44, 46 HIV-SN has been hitherto thought to result from 2 clinically indistinguishable neuropathies with distinct pathogenesis: a distal axonal degeneration caused by interaction of sensory neurones with HIV proteins eg, HIV glycoprotein gp120 3, 16, 22, 31, 37, 45, 47 and ART-induced toxic neuropathy associated with nucleoside reverse transcriptase inhibitors (NRTIs). 21, 23, 48 Since NRTI introduction, the morbidity and mortality of HIV infection have been markedly reduced. 21 Although certain d-NRTIs such as zalcitabine (ddC) and stavudine (d4T) 17, 48 are undoubtedly neurotoxic, the prevalence of HIV-SN in resourcerich settings did not decline in patients who have never been exposed to these drugs, 9, 21 suggesting that alternative or additional factors may underlie HIV-SN in the clinical setting. Protease inhibitors are regularly used as a part of combinational ART. A number of studies have linked exposure to protease inhibitor medication to HIV-SN risk, 8, 28, 38, 44 including a demonstration of indinavir potentiating the neurotoxicity of HIV in a transgenic rat model using cultured dorsal root ganglia (DRG). 38, 50 Thus, HIV-infected DRG cultures exposed to indinavir showed significant neuronal atrophy, neurite retraction, and process loss, compared with controls. However, this association between protease inhibitors and HIV-SN also remains far from clear. A review of adults initiating combinational ART in AIDS Clinical Trials Group (ACTG) studies found HIV-SN risk was only increased by protease inhibitor use if the patient was also using at least one neurotoxic d-NRTI. 13 Further analysis of patients involved in the US-based CHARTER (CNS HIV AntiRetroviral Treatment Effects Research) cohort found small, if any, independent effect of protease inhibitor exposure on HIV-SN risk. 11 Rat models have been used to understand the pathogenesis of HIV-SN and to develop novel therapeutics for HIV-SN. [17] [18] [19] [20] 22, [47] [48] [49] [50] Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Here, we hypothesised that systemic indinavir treatment in rats would produce signs of peripheral neuropathy and neuropathic pain-like behaviours. Initially, we validated the approach in behavioural studies, which showed that indinavir-treated rats developed hind paw mechanical and cold, but not heat, hypersensitivity and pain-related aberrations in complex, ethologically relevant thigmotactic behaviour. 17, 47, 48 We then elucidated the clinical diagnostic feature of a length-dependent "dying back" small fibre axonal neuropathy by demonstrating loss of epidermal innervation after indinavir treatment.
Materials and methods

Ethical statement
Animal experiments were conducted in accordance with the United Kingdom law (Animal Scientific Procedures Act 1986; Project License PPL70/7162) and IASP guidelines. 52 The ARRIVE reporting guidelines were followed. 24 
Experimental animals
Temperature-controlled standard rat IVC cages (21˚C, 2-3 per cage) with corncob bedding were used for housing the animals (male adult Wistar rats; 200-300 g; Charles River, Margate, United Kingdom). We did not use environment enrichment. Rats were kept on a 12:12 hours light-dark cycle. Normal rat chow (RM1 pellets; Special Diet Services, Essex, United Kingdom) and tap water ad libitum were provided. Animals were allowed to acclimatise for 48 hours after delivery.
Study design
To reduce experimental bias, we followed major domains of Good Laboratory Practice 29, 42 (Supplementary Table 1 , available online at http://links.lww.com/PAIN/A346). Behavioural experiments were performed in the light phase in the behavioural laboratory, and intravenous (i.v.) and intraperitoneal (i.p.) injection procedures were conducted in the surgical laboratory, all at Imperial College London (Chelsea and Westminster Campus). We used batches of subset experiments (normally 2-3 animals per group) for thigmotaxis. Sequences of A-B-C then C-B-A (letters assigned to mask the cage labels during testing) were used to select animals.
Indinavir administration
Under general anaesthesia (1%-2% isoflurane [Abbott, United Kingdom] in O 2 and N 2 O ratio 1:1), indinavir (0.5 mL; 50 mg/kg in sterile saline; donated by Pfizer Ltd, Sandwich, United Kingdom) was administered through a tail vein. Four days later, a second injection of indinavir was performed at the same dose and volume. Control animals were given sterile saline at equivalent volumes. Previous animal data with other antiretroviral drugs have shown that oral gavage and i.v. routes result in comparable nocifensive behavioural profiles. 18 Therefore, we decided to use the i.v. route, which would minimise handling stress caused by oral gavage. The dose and treatment regime were chosen based on previous studies with ddC and d4T. 17, 18, 48 
Hind paw mechanical hypersensitivity
The procedure to assess hind paw withdrawal to mechanical stimuli was the same as in our previous study. 48 An electronic "von Frey" device (0.5 mm 2 probe tip area; Somedic Sales AB, Hörby, Sweden) was used to measure the withdrawal threshold in response to punctate static mechanical stimulation. We performed 2 habituation sessions (40-50 minutes each) and then 2 baseline (BL) tests. Animals were placed in plexiglass boxes (23 3 18 3 14 cm) with 0.8-cm-diameter mesh flooring for acclimatisation. When exploratory behaviour ceased, the probe was used to deliver an increasing force (rate of 8-15 g/s) and was applied to the midplantar until the animal actively withdrew the paw. This was repeated 5 times at 1 minute interval between each application.
Hind paw cold hypersensitivity
Cold hypersensitivity was assessed using the acetone drop method. 5 Animals were placed in plexiglass boxes (23 3 18 3 14 cm) with 0.8-cm-diameter mesh flooring and allowed to acclimatise for 15 minutes or until exploratory behaviour ceased. The cooling stimulus was a single bubble of acetone applied to the midplantar surface of each hind paw delivered from the tip of a 1 mL syringe. A positive response was recorded when the rat withdrew its paw after the acetone application. For each measurement, 5 acetone drop applications were delivered and a mean limb withdrawal rate calculated. At least 3 minutes were allowed to elapse between each test.
Hind paw response to noxious heat
Hypersensitivity to noxious heat was assessed by measuring the limb withdrawal time after application of an infrared heat stimulus (Plantar test, Ugo Basile, Varese, Italy, Hargreaves et al., 1988). Briefly, animals were placed in a clear plexiglass box (23 3 18 3 14 cm) with a dry glass floor and allowed to acclimatise for 15 minutes or until exploratory behaviour ceased. A focused infrared beam (46˚C, wavelength 50 nm) was delivered to the plantar surface of the hind paw. The paw withdrawal latency (s) to this stimulus was tested 3 times at intervals of not less than 3 minutes and a mean withdrawal latency calculated. To avoid thermal injury, an automatic cut-off time of 21 seconds was set.
Thigmotactic behaviour
The rationale of thigmotaxis as a predator avoidance ethologically relevant behavioural outcome measure in rodent pain studies has been previously described. 17 At PID 15, the rats were introduced for the first time to the 100 3 100 cm open field arena, which was lit to a light intensity of 12 lux. Locomotor activity was then recorded for 15 minutes using a high-sensitivity Sanyo camera (VCB 3372, Sanyo, Akaiwa, Japan). EthoVision software (v.4.1, Tracksys Ltd, United Kingdom) was used to track the movement of animals in the arena, and to calculate the frequency of entry and time spent in the virtual central zone (40 3 40 cm) as well as the total distance travelled in the whole open field arena.
Pharmacological validation
Animals received i.p. injections of either analgesic drugs or vehicle solutions twice per day (b.d.) between PID 12 and 15, during which the hind paw withdrawal thresholds were measured in response to punctate static mechanical stimulation once per day at 1.5 to 2 h after the first injection. We chose to test gabapentin (0.5 mL; 30 mg/kg in sterile saline; a gift from Pfizer Ltd) and amitriptyline (0.5 mL; 10 mg/kg in sterile saline; Sigma, Dorset, United Kingdom), based on previous studies and clinical trials. 
Immunohistochemistry and quantitative analysis
The procedures for tissue processing, immunohistochemistry, and quantitative analysis were the same as previously described. 17 Briefly, at PID 14, we terminally anaesthetised some animals with sodium pentobarbital, and then transcardially perfused them using 4% paraformaldehyde. After perfusion, we removed L5 spinal cord, L5 DRG, and glabrous hind paw skin, and then postfixed the tissue in 4% paraformaldehyde overnight. We then used 30% sucrose in phosphate-buffered saline (PBS) to cryoprotect the tissue for 72 hours. Cryostat sections of optical coherence tomographyembedded tissue were cut (spinal cords at 20 mm, DRG at 10 mm, skin at 14 mm) and collected on superfrost slides. Sections were incubated with 10% normal donkey serum for 60 minutes followed by overnight incubation with the following appropriate primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP) (1:1000; Dako, Ely, United Kingdom), rabbit anti-calcitonin generelated peptide (CGRP) (1:2000; Sigma), rabbit anti-Iba1 (1:1000; WAKO, Osaka, Japan), rabbit protein gene product (PGP) 9.5 (1:1000; Ultraclone Ltd, Cambridge, United Kingdom). After 3 PBS washes, sections were incubated with appropriate secondary donkey anti-rabbit Cy3 or fluorescein isothiocyanate antibodies (1: 400; Stratech, Newmarket, United Kingdom) for 2 hours. Biotinconjugated isolectin B4 (IB4; 0.5 mg/mL used at 1:50; Sigma) and ExAvidin-fluorescein isothiocyanate (1:400; Sigma) were used to detect nonpeptidergic C-fibres in the skin. After 3 PBS washes, slides were cover-slipped with Vectashield mounting medium (Vector Laboratories, Peterborough, United Kingdom) and visualised under a Zeiss Axioplan 2 fluorescent microscope (Zeiss, United Kingdom).
The experimenter who performed quantitative analysis was blind to treatment groups. We used 4 areas (50,000 mm 2 each) in the superficial dorsal horn and 4 areas (1500 mm 2 each) in the DRG from 5 to 7 randomly selected sections per rat to quantitatively analyse Iba1 immunoreactive cell numbers. We classified Iba1 immunoreactive cells in the dorsal horn as having "effector" morphology when their process lengths were less than double the soma diameter. In contrast, we classified Iba1 immunoreactive cells in the dorsal horn as having "resting" morphology when their process lengths were double the soma diameter. We used 6 to 8 randomly selected sections from L5 dorsal horn per rat to analyse the intensity of GFAP immunoreactivity that was expressed in arbitrary units. We also measured the intensity of IB4 or CGRP immunoreactivity in laminae I and II. We used 6 to 8 DRG sections per rat to analyse IB4/CGRP expression. The number of IB41 or CGRP1 cells was expressed as a percentage of the total DRG cells. We only sampled DRG cells with visible nucleus and distinctly delineated borders. We live-counted PGP9.51 epidermal fibres at 40X objective magnification using the method described previously. 27 Thus, we only counted single fibres crossing the dermal-epidermal junction without secondary branches. Then the epidermal innervation density (intraepidermal nerve fibre density [IENFD]/mm) was calculated based on the epidermis length measure by ImageJ software 1.45 (National Institutes of Health).
For investigating the expression of phospho-p38 (pp-38) in microglia, spinal cord sections were incubated overnight with rabbit anti-pp-38 primary antibody (1:100; Cell Signaling Technology, Danvers, MA), which was then amplified using a TSA Biotin System (Perkin Elmer, United Kingdom). The slides were then incubated with rabbit anti-Iba1 (1:1000) primary antibody, followed by corresponding secondary antibody (1:400) solution. Double staining images were taken at 320 objective magnification using a Leica DMR light microscope (Leica Microsystems, Milton Keynes, United Kingdom). The number of cells immunoreactive for both pp-38 and Iba1 in the superficial dorsal horn was counted using Photoshop CS5 (Adobe, San Jose, CA) and expressed as a percentage of Iba1 immunoreactive cells.
Statistics
Statistical analysis for the behavioural study data was performed using IBM SPSS Statistics Version 23. For the mechanical, cold, and heat hypersensitivity as well as the pharmacological validation study, 2-way ANOVA was used to examine the main effects of treatments, times, and interaction between treatments and times where appropriate. The Tukey-Kramer post hoc multicomparison adjustment was used to determine if there was any significant difference between treatment groups, ie, vehicle vs indinavir, and saline vs gabapentin or amitriptyline. For the thigmotaxis study, 1-way ANOVA followed by Tukey-Kramer post hoc multicomparison adjustment was used to evaluate if there was a main treatment effect and if significant differences between groups (indinavir, vehicle, and naive) existed. In addition, we included the total distance moved in the open field arena as a secondary outcome for the thigmotactic analysis. The box and Figure 1 . The development of hind paw hypersensitivity to punctate mechanical stimuli after indinavir treatment. We measured the withdrawal thresholds at the baseline (BL) and after indinavir (50 mg/kg, twice at 4 days apart) or vehicle administration. Two-way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to determine the difference between treatment groups. *Significant difference from the vehicle group (P , 0.05); ‡Significant difference from the baseline (P , 0.05). Figure 2 . The development of hind paw hypersensitivity to cold stimuli after indinavir treatment. We measured withdrawal responses at the baseline (BL) and after indinavir (50 mg/kg, twice at 4 days apart) or vehicle administration using an acetone drop. Two-way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to determine the difference between treatment groups. *Significant difference from the vehicle group (P , 0.05); ‡Significant difference from the baseline (P , 0.05). scatter plots for the thigmotaxis data were made using OriginPro 2016 (OriginLab, Northampton, MA). All measurements are expressed as mean 6 SEM in the Result section. In addition, behavioural data are presented using 95% confidence levels in the Supplementary Table 3 (available online at http://links.lww.com/ PAIN/A346). P , 0.05 was considered as statistically significant. For histological analysis, differences between vehicle-and indinavir-treated animals were determined using a nonparametric test, the Wilcoxon-Mann-Whitney test. We report our data as mean 6 SEM and consider P , 0.05 as statistically significant.
Results
No animals were excluded from this study according to the inclusion and exclusion criteria set in the Supplementary Table 1 (available online at http://links.lww.com/PAIN/A346). A summary of group sizes and primary outcome measures is in Supplementary Table 2 (available online at http://links.lww.com/PAIN/A346).
Indinavir treatment results in hind paw hypersensitivity to mechanical stimuli
To investigate the effect of indinavir treatment in mechanical sensitivity of rats, we tested animals that have and have not received the drug for up to 42 days using an electronic "von Frey" device. We observed that rats treated with indinavir (n 5 6) developed bilateral hind paw mechanical hypersensitivity, which occurred from PID 4 and reached a peak at PID 14 ( Fig. 1) . Withdrawal thresholds were changed from the BL at 226%, No hind paw hypersensitivity to thermal stimuli after indinavir treatment. We measured withdrawal responses at the baseline (BL) and after indinavir (50 mg/kg, twice at 4 days apart) or vehicle administration using a noxious thermal stimulus (Hargreaves device). Two-way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to determine the difference between treatment groups. *Significant difference from the vehicle group (P , 0.05); ‡Significant difference from the baseline (P , 0.05).
233%, 239%, 244%, 236%, and 226% for PID 4, 7, 11, 14, 28, and 35, respectively. Here, we did not observe significant difference in mechanical hypersensitivity between the left and right hind paws (data not shown). Therefore, we pooled the withdrawal thresholds from both hind paws. The hind paw mechanical hypersensitivity after indinavir treatment was maintained until PID 42, and then the thresholds showed a trend returning to the BL. The statistical analysis revealed significant effects of treatments, times, and the interaction between treatments and times on hind paw mechanical hypersensitivity development (for treatment
Indinavir treatment results in hind paw hypersensitivity to cold stimuli
To examine if indinavir treatment could lead to changes in cold sensitivity, we tested treated vs untreated animals using the acetone test. We observed that rats treated with indinavir (n 5 6) developed bilateral hind paw cold hypersensitivity, which occurred from PID 6, plateaued between PID 13 and 31, and then maintained between PID 41 and 45 (Fig. 2) . Mean percentage changes of the percentage response to cold stimuli from the BL were 214%, 286%, 515%, 529%, 650%, 487%, 501%, 258%, and 258% for PID 6, 9, 13, 17, 21, 24, 31, 41, and 45, respectively. We did not observe significant difference in cold hypersensitivity between the left and right hind paws (data not shown). Therefore, we pooled the thresholds from both hind paws. The statistical analysis revealed significant effects of treatments, times, and the interaction between treatments and times on hind paw cold hypersensitivity development (for treatment: P 5 0.0001, df 5 1, F 5 1212.65; for time: P 5 0.0001, df 5 9, F 5 16.95; for interaction between treatment and time: P 5 0.0001, df 5 9, F 5 17.28).
Indinavir treatment does not induce heat hypersensitivity
We next tested if indinavir treatment results in changes in heat sensitivity. In contrast to the development of hind paw mechanical and cold hypersensitivity after indinavir treatment, we did not observe increased hind paw responses to noxious thermal stimuli using the Hargreaves device in indinavir-treated animals (n 5 6) as compared with the BL and that of the vehicle-treated animals (n 5 6) (Fig. 3) . The statistical analysis revealed no significant effects of treatments, times, and the interaction between treatments and times on hind paw heat hypersensitivity development (for treatment: P 5 0.474, df 5 1, F 5 0.554; for time: P 5 0.935, df 5 5, F 5 0.255; for interaction between treatment and time: P 5 0.911, df 5 5, F 5 0.299).
Thigmotaxis was increased after indinavir treatment
An open field apparatus was used to assess the impact of indinavir treatment on thigmotactic behaviour. Such behaviour has been previously shown to be associated with pain behaviour in animal models of nerve trauma, varicella zoster virus, HIV gp120, and antiretroviral drugs. 15, 17, [47] [48] [49] [50] Here, we showed that animals treated with indinavir (n 5 8) established hind paw mechanical hypersensitivity at PID 14 (indinavir: BL 5 44.6 6 0.7 vs PID 14 5 25.8 6 0.6, P , 0.05; vehicle: BL 5 45.5 6 0.6 vs PID 14 5 45.3 6 0.7, P . 0.05). Then at PID 15, we showed a significant treatment effect on thigmotaxis behaviour using statistical analysis (P 5 0.021, df 5 2, F 5 4.671). Thus, at PID 15, track pattern analysis using entry number and time spent in the virtual inner zone demonstrated a significant effect of indinavir on spontaneous explorations. Animals that received indinavir treatment had much lower number of entry (4.0 6 1.3) and less time spent (5.0 6 1.7 seconds) in the virtual zone in contrast to the naive (n 5 8, 11.4 6 1.7 and 12.8 6 1.9 seconds; P , 0.05, ANOVA/Tukey-Kramer post hoc test) and vehicle-treated (n 5 8, 10.5 6 1.9 and 11.4 6 1.5 seconds; P , 0.05, ANOVA/Tukey-Kramer post hoc test) animals (Fig. 4) . We did not observe any difference in the total distance travelled in the open field among the groups at PID 15 (indinavir 7326.5 6 12.8 cm vs naive 7602.1 6 23.6 or vehicle 7513.9 6 18.5 cm, P . 0.05), which is in line with our previous data. 17, 47, 48 
Effects of analgesic drugs on hind paw hypersensitivity
We examined the pharmacological validity of our model using analgesic drugs, which have been shown either effective or not effective in the clinic for treating HIV-SN. 40 First, we demonstrated that amitriptyline was not effective in reversing hind paw mechanical hypersensitivity in animals treated with indinavir (Fig. 5) . The 
Indinavir treatment results in reduced epidermal innervation of hind paw skin
We applied PGP 9.5 immunostaining to visualise unmyelinated fibres in the hind paw skin. After indinavir treatment (n 5 6) at PID 14, there was a significant reduction in IENFD, suggesting a withdrawal of unmyelinated axons from the epidermis when compared with that of the vehicle-treated animals (n 5 6) (Wilcoxon-Mann-Whitney test, P 5 0.02; Fig. 6 ).
Systemic indinavir induces a minimal spinal microglial response and no inflammatory cell response in the DRG
We examined if a glial cell response in the dorsal horn could be induced by systemic treatment of indinavir. We stained L5 sections with the microglial marker Iba1, and then counted the cells in the superficial dorsal horn exhibiting "effector" morphology, ie, cell body hypertrophy and process retraction. We found that indinavir-treated rats had significantly increased numbers of microglia with "effector" morphology (indinavir: 7.66 6 0.61 vs vehicle: 2.80 6 0.31 cells per 50,000 mm 2 , n 5 5 per group, P 5 0.0001, Wilcoxon-Mann-Whitney test; Fig. 7 ). There appeared no difference in Iba1 immunoreactivity in other areas of the spinal cord ( Supplementary Figures 1 and 2 , available online at http://links.lww.com/PAIN/A346). Then we assessed microglial activation by looking at pp-38 expression. Double immunostaining showed a significant increase in the number of microglia positive for pp-38 in animals treated with indinavir in comparison with the controls at PID 14 (indinavir: 41.41 6 7.68% vs vehicle: 6.65 6 2.15%; n 5 5, Wilcoxon-MannWhitney test, P 5 0.008; Fig. 8 ). The level of this increase is much less in contrast to that after spinal nerve ligation (Fig. 8) .
We also investigated the astrocytic response to indinavir and found that there was no difference in GFAP immunoreactivity in the dorsal horn between the indinavir-treated and control groups at PID 14 (indinavir 91.39 6 14.27 vs vehicle 100.00 6 14.42, n 5 5 per group, P 5 0.68, Wilcoxon-Mann-Whitney test; Fig. 7) . Nerve injury recruits macrophages into the DRG. Therefore, we examined if such macrophage infiltration accompanied the painful peripheral neuropathy induced by indinavir treatment. We found that the number of Iba-1 immunoreactive cells in L5 DRG did not increase after indinavir treatment (n 5 5, vehicle 6.5 6 0.45 vs indinavir 7.52 6 0.97, P 5 0.36, Wilcoxon-Mann-Whitney test; Fig. 9 ).
Systemic indinavir does not alter IB4 and CGRP expression of lumbar spinal cord and DRG
We examined the expression of neurochemical markers for different DRG cell populations after indinavir treatment. Nonpeptidergic and peptidergic small-diameter DRG cells can be labeled with IB4 and CGRP, respectively. After nerve trauma, the 2 markers are downregulated. In contrast, here we found no change in the percentages of IB41 DRG cells and CGRP1 DRG cells after indinavir treatment in the lumber spinal cord (n 5 5, IB4: vehicle 100.00 6 8.12% vs indinavir 108.55 6 13.51%, P 5 0.75, CGRP: vehicle 100.00 6 12.13% vs indinavir 90.34 6 19.15%, P 5 0.47, Wilcoxon-Mann-Whitney test in both cases; Fig. 7) . A similar finding was found in the lumber DRG (n 5 5, IB4: vehicle 33.62 6 1.13% vs indinavir 33.98 6 0.50%, P 5 0.76, CGRP: vehicle 31.52 6 1.05% vs indinavir 31.82 6 1.19%, P 5 0.86, Wilcoxon-Mann-Whitney test in both cases; Fig. 9 ).
Discussion
Pharmacological agents such as drugs inhibit the protease activity of HIV (eg, indinavir) are key components of drug therapy for patients with HIV. However, limited clinical observations and one in vitro study suggest that indinavir exposure might increase the risk for HIV-SN.
11,28,38,40, 44 We, and others, have previously extensively described the neurotoxicity associated with the d-NTRI group of antiretroviral drugs. However, we are the first who have comprehensively documented in vivo the neurotoxicity associated with wholly different class of antiretroviral drugs, the protease inhibitors, which were hitherto hinted at the abovementioned limited evidence, but in the main were not suspected of being neurotoxic. Our study provides the first in vivo evidence of an indinavir-induced peripheral neuropathy in a rodent model. Here, we have shown a persistent painful peripheral sensory neuropathy developed in indinavir-treated animals that had no motor deficits, resembling a major clinical problem in HIV management. In accordance with the clinical presentation, we have shown not only simple reflex pain behaviour, which was sensitive to pharmacological perturbation, but also a complex thigmotactic behaviour associated with pain. Furthermore, we have shown, using histology, that our model is characterised by a retraction of epidermal axons, which is an established clinical diagnostic technique for HIV-SN 41 and other peripheral neuropathies that have a small fibre component. 25, 33 We have also demonstrated a small but significant microglial response in indinavir-treated animals at the time of peak hind paw mechanical hypersensitivity. Prominently, this neurotoxicity seen in our model happens independently of HIV infection. The latter is a difficult confound to dissect in patients, because not only the 2 conditions coexist, but also HIV and sensory neurons interaction can cause painful neuropathy. 39, 48 Here, we have observed both mechanical and cold, but not heat, hypersensitivity in the hind paws of indinavir-treated animals, contrasting to animal models of NRTIs-induced peripheral neuropathy, which shows only hind paw mechanical hypersensitivity. 17, 18, 48 This finding is also in contrast with early clinical data showing that patients with HIV-related painful neuropathy do not usually present with thermal hypersensitivity. 32 Our recent study involving a cohort of HIV-infected patients with and without HIV-SN, most of whom had received combinational ART including indinavir, has shown that the most frequent sensory abnormalities demonstrated in the HIV-SN group are loss of mechanical and vibration detection thresholds followed by a significant loss of cold and warm detection thresholds and heat pain threshold when compared with those of neuropathy-free HIV-positive patients and healthy volunteers, demonstrated by quantitative sensory testing. 39 The same study has also shown that although the presence of gain-of-sensory function is rare across all groups, a small minority of patients have features of mechanical windup ratio in patients with HIV-SN. Subgroup analysis of a randomized controlled trial of pregabalin in HIV-SN has reported a small group of patients with signs of mechanical sensory gain. 43 Furthermore, using the Neuropathic Pain Symptom Inventory, it has been revealed that 42% of participants experiencing painful HIV-SN report symptoms of moderate and severe cold-evoked pain, although this is not detected with sensory profiling. 39 Here, we have shown that indinavir-treated rats display increased thigmotaxis in the open field at the time of peak hind paw mechanical hypersensitivity. This suggests the presence of pain-driven alterations in affect, which may be representative of ongoing pain and/or painrelated affective comorbidities, which are known to be a feature of neuropathic pain in humans. 14, 34, 35 Indeed, our recent study has shown that participants with painful HIV-SN have reduced quality of life, a higher incidence of insomnia, and increased depression, anxiety, and catastrophizing, when compared with participants without HIV-SN. 39 Previously, it has been shown that in cultures of CD4 and CCR5 expressing rat DRG neurons infected with HIV-1 with subsequent treatment by indinavir, there is a marked reduction of neurites numbers and lengths, suggesting additive neurotoxic effects by indinavir. 38 Indinavir-treated DRG cultures also showed numerous TUNEL (an apoptosis marker)-positive nuclei in cells that were ED-1 (a macrophage marker) immunoreactive, suggesting that resident DRG macrophages may be targets of indinavir toxicity. In this study, no DRG abnormalities were observed after indinavir administration, ie, no change in CGRP1 or IB41 neurons or in macrophage infiltration, which markedly contrasts to nerve trauma models. Furthermore, no changes were found in the central projections of primary afferents after indinavir treatment. Thus, we did not observe reduced CGRP expression and IB4 binding in L5 dorsal horn, where primary afferents from hind paws end. This finding is in contrast to significant reductions in CGRP/IB4 immunoreactivity in L5 spinal dorsal horn seen in animals treated with d4T. 17 Activation of the innate immune system in the dorsal horn of the spinal cord is key in the development of pain after nerve injury. 2, 6 However in the case of indinavir treatment, we only observed a small but significant increase (1.7 fold) in microgliosis; we observed an increased microglial expression of pp-38, which is known to promote the microglial proinflammatory responses to produce mediators such as COX-2, IL-1b, brain-derived neurotrophic factor, and iNOS, contributing to neuropathic pain development and maintenance. 6 We did not observe any evidence of astrocyte response to indinavir treatment. Our observation of a minimal glial and immune response in the spinal cord and DRG after indinavir treatment is comparable with those reported in chemotherapy or metabolic agents induced chronic painful neuropathy, 4, 6, 17, 51 highlighting the need for relevant animal models to address particular clinical scenarios.
Importantly, here indinavir administration resulted in a reduction in hind paw IENFD, which is also manifested in many other painful neuropathies, 26 such as SN resulted from ddC 48 and d4T 17 treatment, and direct neurotoxicity mediated by HIV virus. 47 Reduced IENFD, a key clinical diagnostic tool for HIV-SN, correlates inversely with neuropathic pain progress. 39, 41 There is evidence suggesting that protease inhibitors are associated with insulin resistance and resultant diabetic complications in patients with HIV, 7 which is thought to be mediated through the inhibition of insulin-regulated glucose transporter. 10 Therefore, it is possible that such diabetic complications could also result in Table 1 Comparison of key neurochemical markers in the lumbar spinal cord and DRG between indinavir and d4T models at the time of peak hind paw mechanical hypersensitivity. the development of diabetic peripheral sensory neuropathy with a characteristic loss of IENFD on skin biopsy. 36 In this study, we found no significant difference in blood glucose levels and body weights at PID 19 and PID 45 between indinavir-treated and vehicle-treated animals (data not shown), suggesting that the dose regime of indinavir in our study did not cause insulin resistance.
Our study could explain the well-documented persistence of painful peripheral neuropathy in patients who have not been exposed to d-NRTIs or who were not susceptible to d-NRTI neurotoxicity, which had hitherto been assumed to be the main cause of neurotoxicity. Our study also highlights the importance of using animal models to study cause of the neurotoxicity of protease inhibitors in isolation, since there are too many confounds in patients because they have concomitant HIV disease and also take a plethora of other drugs, including a combination of antiretroviral drugs. We chose to explore indinavir, one of the prototypical protease inhibitors, as it is representative of the class. However, we acknowledge that in well-resourced settings, it has been replaced by new generation protease inhibitors, and it has also been replaced by other protease inhibitors on the World Health Organization's List of Essential Medicines. However, there is still a huge clinical legacy of patients who had been exposed to it and who have persistent peripheral neuropathy that requires clinical management. We do not know whether the neurotoxicity which we demonstrated as being associated with indinavir is a PI class effect or unique to indinavir-that is for further studies. Here, we have not studied the dose effect for indinavir, as the purpose of this report is to test whether indinavir can produce neurotoxicity in isolation rather than mimic the patient living with HIV. The dose of 50 mg/kg was chosen to keep consistency with our previous ddC and d4T studies and is likely to underestimate the human dose if converted using surface area dosage conversion. However, we agree that a dose effect study is important to expand the testing of our hypothesis and will be included in future studies along with ddC and d4T. We also agree that electron microscopy studies might be useful in yielding further information, but are outside the scope of this study.
In summary, we have established a rodent model of painful SN mediated by systemic indinavir treatment. Our model mimics a number of clinical features and reveals important mechanistic differences when compared with the previously reported d4T model ( Table 1) . HIV-SN continues to be one of the most prevalent morbidities experienced by people living with HIV in both high-and low-resource settings. Our model offers an important tool to better comprehend the pathogenesis, develop preventive strategies, and discover effective drugs for HIV-SN.
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